Table 2

Clinical response to anti-PD-1-based therapy in metastatic sarcomas

Response12WOverall response
CR00
PR43
SD97
PD58
Excluded66
ORR22.2% (4/18)16.7% (3/18)
DCR72.2% (13/18)55.6% (10/18)
PFR−12W = 49.8%mPFS = 7.59 month
mOS unreached

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; ORR, objective response rate; PFR, progression-free survival; mPFS, median progression-free survival.